Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B. Daly, Mary A. Dwyer, Michael Goggins et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1.1k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Minetta C. Liu et al.|JAMA Oncology|2020Cited by 707
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Laura J. Esserman, Christina Yau et al.|Cancer Cell|2021Cited by 330
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline UpdateN. Lynn Henry, Angela DeMichele, Mark R. Somerfield et al.|Journal of Clinical Oncology|2022Cited by 127